Invivogen
Menu

(Denosumab biosimilar - IgG2 isotype)

Product Unit size Cat. code Docs. Qty. Price

Anti-hRANKL-hIgG2

Human RANKL (Denosumab) antibody - Human IgG2

Show product

100 µg

1 mg

hrankl-mab2
+-
$109

Human IgG2 monoclonal antibody (mAb) against human RANKL (TNFSF11)

Effector functions of mAb isotypes targeting CD20

Anti-hRANKL-hIgG2 is the biosimilar of the clinical antibody denosumab. Anti-hRANKL-hIgG2 features a human IgG2 constant region (Fc) and the variable region of denosumab which targets the transmembrane and soluble forms of the human RANKL (receptor activator of nuclear factor-κB ligand) antigen. RANKL is also known as member 11 of the tumor necrosis factor ligand superfamily (TNFSF11) [1]. RANKL binding to its receptor RANK induces signaling in osteoclasts and is responsible for bone resorption. RANKL-RANK also plays a pivotal role in dendritic cell maturation and T-cell differentiation [2]

Denosumab is a fully human IgG2 mAb that blocks the interaction of hRANKL with its receptor RANK and thus the downstream signaling. Human IgG2 is the second most common antibody present in serum. It is resistant to cleavage by proteolytic enzymes, due to a short hinge region. This isotype displays low complement-dependent cytotoxicity (CDC), very low antibody-dependent cellular phagocytosis (ADCP), and very low antibody-dependent cellular cytotoxicity (ADCC).
Denosumab has been approved by the FDA for the treatment of osteoporosis and bone metastasis.

 

InvivoGen's Anti-hRANKL-hIgG2 is generated by recombinant DNA technology, produced in Chinese hamster ovary (CHO) cells, and purified by affinity chromatography (protein G).

More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see below or in the 'upon request' section). 

 

 Read our review on Antibody Isotypes

 

References:

1. Ahern E. et al., 2018. Roles of the RANKL-RANK axis in antitumour immunity -implications for therapy. Nat Rev Clin Oncol. 15(11):676-693.
2. Cheng ML. & Fong L., 2014. Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol. 3:329.

Figures

Validation of Anti-hRANKL-hIgG2 mAb by ELISA
Validation of Anti-hRANKL-hIgG2 mAb by ELISA

Binding of Anti-hRANKL-hIgG2 mAb to coated human RANKL protein. Human RANKL (1 µg/ml) was coated on ELISA plates overnight. A 3-fold serial dilution of the  Anti-hRANKL-hIgG2 mAb (red curve) or the Anti-β-Gal-hIgG2 control antibody (grey curve) was performed for the capture step. An HRP-labelled anti-hIgG antibody (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride) were used for the detection step. Absorbance was read at 490 nm.

Dose-dependent neutralization of RANK/RANKL signaling
Dose-dependent neutralization of RANK/RANKL signaling

Dose-dependent inhibition of HEK‑Blue™ RANKL cellular response using the Anti-hRANKL-hIgG2 antibody.

Increasing concentration of InvivoGen's Anti-hRANKL-hIgG2 antibody was incubated with HEK‑Blue™ RANKL cells for 30 minutes before the addition of 10 ng/ml of hRANKL. After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI‑Blue™ Solution. Data represent % inhibition of reporter activity without anti-hRANKL antibody.

Back to the top

Specifications

Target: Human receptor activator of nuclear factor-κB ligand (RANKL, TNFSF11, CD254)

Clonality: Monoclonal antibody

Clone: Denosumab (anti-hRANKL-hIgG2, kappa)

Isotype: Human IgG2, kappa

Control: Human IgG2

Source: CHO cells

Formulation: 0.2 µm filtered solution in 68 mM sodium phosphate buffer (pH 7.4) with 91 mM glycine, 5% w/v saccharose, and stabilizing agents

Purity: Purified by affinity chromatography with protein G

Tested applications: ELISA, neutralization assay

Quality control:

  • Binding of Anti-hRANKL-hIgG2 to human RANKL has been confirmed using ELISA and neutralizing cellular assays.
  • The complete sequence of this antibody has been verified.
  • The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Back to the top

Contents

Anti-hRANKL-hIgG2 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

  • hrankl-mab2: 100 µg
  • hrankl-mab2-1: 1 mg

room temperature Anti-hRANKL-hIgG2 is shipped at room temperature.

store Upon receipt, store at -20°C.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty